These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 6367665

  • 1. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS, Gilgor RS, Allen LM, Duvic M.
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [Abstract] [Full Text] [Related]

  • 2. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study.
    Russell IJ, Lessard JA.
    J Rheumatol; 1985 Feb; 12(1):94-8. PubMed ID: 3884807
    [Abstract] [Full Text] [Related]

  • 3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 4. DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon.
    Pisenti L, Hart LL.
    Drug Intell Clin Pharm; 1984 Mar; 18(3):213-4. PubMed ID: 6365494
    [No Abstract] [Full Text] [Related]

  • 5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J, Rovenský J, Tauchmannová H, Zitnan D.
    Drugs Exp Clin Res; 1985 Mar; 11(9):659-63. PubMed ID: 3916837
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Raynaud's phenomenon with captopril.
    Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C.
    Drugs Exp Clin Res; 1987 Mar; 13(1):37-42. PubMed ID: 3297593
    [Abstract] [Full Text] [Related]

  • 7. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA, Mellinger S, Kohler J, Dorsey JK, Furst DE.
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [Abstract] [Full Text] [Related]

  • 8. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A, Amor B, Menkès CJ.
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [Abstract] [Full Text] [Related]

  • 9. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N.
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J, Blétry O, Guillevin L, Lacombe C, Fraitag B, Duloroy J, Mouthon JM, Godeau P.
    Ann Med Interne (Paris); 1986 May; 137(3):260-3. PubMed ID: 3532900
    [Abstract] [Full Text] [Related]

  • 11. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R, Shariat K, von Wilmowsky H, Böhm M.
    Circulation; 2005 Nov 08; 112(19):2980-5. PubMed ID: 16275885
    [Abstract] [Full Text] [Related]

  • 12. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000 Nov 08; 1998(2):CD000956. PubMed ID: 10796398
    [Abstract] [Full Text] [Related]

  • 13. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E, Letizia C, Proietti M, Aversa A, Menghi G, Rossi C, Torella E, Cotesta D, Petramala L, Bruzziches R, Spera G, Pisarri S, Salsano F.
    J Biol Regul Homeost Agents; 2009 Nov 08; 23(1):23-9. PubMed ID: 19321043
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A, Amor B, Menkes CJ.
    Ann Rheum Dis; 1985 Jan 08; 44(1):30-3. PubMed ID: 3882061
    [Abstract] [Full Text] [Related]

  • 17. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A, McCans J, Willan AR, Ford PM.
    J Rheumatol; 1985 Aug 08; 12(4):724-7. PubMed ID: 3903157
    [Abstract] [Full Text] [Related]

  • 18. Prazosin treatment of primary Raynaud's phenomenon.
    Nielsen SL, Vitting K, Rasmussen K.
    Eur J Clin Pharmacol; 1983 Aug 08; 24(3):421-3. PubMed ID: 6345178
    [Abstract] [Full Text] [Related]

  • 19. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A, Weber S, Amor B, Menkes CJ, Hodara M, Degeorges M.
    Int Angiol; 1985 Aug 08; 4(2):221-3. PubMed ID: 3831143
    [Abstract] [Full Text] [Related]

  • 20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep 08; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.